Healthcare
PROCEPT BioRobotics Corporation(PRCT)
Live Price
Offline$21.72
+3.87% today
1Y Change
-63.93%
Window
Jun 20, 2025 โ Jun 18, 2026
- Market Cap
- $1.40B
- Revenue Growth
- +37.2%
- EPS Growth
- +1.7%
- Dividend Yield
- 0.0%
Coverage: 250 bars ยท Jun 20, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PROCEPT BioRobotics Corporation (PRCT) is a Healthcare stock with a market cap of $1.40B and listed on NASDAQ. The stock last traded around $21.72 and down 63.9% across the available one-year price window (Jun 20, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +37.2%, EPS growth of +1.7%, a dividend yield of 0.0%. What stands out right now is revenue +37.2%, EPS +1.7%, free cash flow +43.7% with operating margin -33.9% and ROIC -25.7%. Valuation sits in the middle of the pack at price/sales 4.4. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PRCT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+37.2% vs +7.6% peer median
Operating Margin
Below sector median
-33.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Apr 23, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +37.2% and EPS at +1.7%, with operating margin around -33.9%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.3% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Apr 23, 2026 | โ | +0.5% | -0.8% | +19.3% |
2026 Feb 25, 2026 | -65.6% | -15.1% | -4.6% | -10.4% |
2025 Nov 4, 2025 | +7.3% | -9.7% | -10.5% | -5.3% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRCT
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PRCT Max Drawdown
-65.28%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PRCT and SPY.
Company Overview
PROCEPT BioRobotics Corporation
NASDAQ Global Market
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
- Leadership
- Larry L. Wood
- IPO Date
- Sep 15, 2021
- Employees
- 756
- Street Address
- 900 Island Drive
- Mailing
- San Jose, CA, 94065
- Region
- San Jose, CA, US
- Reporting Currency
- USD
- Investor Line
- 650 232 7200
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 4.4
- Price/Book
- 4.0
Growth
- Revenue
- +37.2%
- EPS
- +1.7%
- Free Cash Flow
- +43.7%
Profitability
- Gross Margin
- 63.0%
- Operating Margin
- -33.9%
- Net Margin
- -31.8%
- ROE
- -27.7%
- ROIC
- -25.7%
Balance Sheet
- Debt/Equity
- 0.15
- Current Ratio
- 6.73
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.